International Cannabis Weekly: 141

• COVID-19: The turning point for global cannabis legalisation.
• Health Canada asks cannabis labs for assistance with COVID-19 testing.
• NIDA to fund research into how COVID-19 affects cannabis consumers.
• Around 200,000 Spanish citizens are without medical cannabis during lockdown.
• Cannabis street prices surge in France following new strict border controls.
• German cannabis industry association warns of medical cannabis shortages.

• DEA to review applications to grow cannabis for research purposes.
• New Zealand opens licence applications for new medical cannabis programme.
• New York State drops recreational cannabis legalisation in annual budget.

• Germany extends application deadline for national cannabis distribution tender.
• EMMAC Life Sciences secures permits to sell medical cannabis in Germany.
• Flowr receives EU GMP certification for its Portuguese cannabis manufacturing facility.
• ACI launches new plans for CBD safety certification in the UK.

• New York and Toronto stock exchanges initiate the process to delist CannTrust.
• Massachusetts regulators to meet to discuss ‘potential relief’ for cannabis businesses.
• World Class acquires controlling interest in Pineapple Express as home-deliveries surge.
• Tilray agrees to release 11 million shares which could drive shareholder dilution.
• Michigan cannabis sales grow month-on-month, but fall short of initial expectations.
• USDA approves hemp plans for two more states and three Native American tribes.
• Cannabis consumers switching to edibles during pandemic.

• Emergency measures help Australian medical cannabis patients access treatment.
• New Zealand allows import of approved medical cannabis vaporisers.
• First medical cannabis capsules made available on prescription in Australia.

• Mexico’s Senate asks Supreme Court to extend the deadline on cannabis legalisation.
• Bermuda increases threshold on medical cannabis imports to 2,000 grams per year.
• Khiron and Tecnológico de Monterrey to launch medical cannabis education platform.

• Lebanon looks to cannabis cultivation to boost nation’s economic outlook.
• Israel fulfills first international export of non-commercial medical cannabis flower.
• Speciality pharmaceutical firm Neuraxpharm partners with Panaxia Labs Israel.
• Halo Labs postpones reporting annual financial results.

• Researchers develop rapid-response biosensor for detecting THC in saliva.
• Study finds most commercial cannabis products too strong for chronic pain relief.
• InMed completes phase one clinical trials for cannabinol topical cream.
• New research investigates the most common adverse reactions to cannabis use.

• Champignon Brands enters agreement to acquire Tassili Life Sciences Corp.
• MindMed acquires exclusive licence to eight LSD clinical trials for anxiety.
• New non-profit psychedelics education and outreach group launches in Denver.

Prohibition Partners LIVE will be the largest cannabis event in the world this summer. We are taking our industry-leading conferences online, delivering you agenda-setting content, targeted virtual networking and engaging digital experiences. All at the touch of a button.

JOIN THE WAITLIST …

Disrupting Beauty, the first report in ‘The Impact Series’ showcasing how cannabis is permeating the mainstream.

Disrupting Beauty documents how cannabis is disrupting the traditional beauty market and the supply chain as demand skyrockets for cannabis beauty products.

Download now…